Real-world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2-year experience

被引:1
|
作者
Fujiwara, Chisako [1 ]
Uchiyama, Akihiko [1 ]
Inoue, Yuta [1 ]
Ishikawa, Mai [1 ]
Motegi, Sei-ichiro [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Dermatol, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan
关键词
PLACEBO;
D O I
10.1002/cia2.12280
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Objective: Dupilumab has been deemed highly effective for atopic dermatitis (AD). However, there have been no reports performing a combination analysis with hematological data and improvement rates pertaining to the continued use of dupilumab for up to 2years in real world. In this study, we evaluated the effectiveness and safety of using dupilumab for up to 2years in 9 patients with AD at our hospital. Methods: Thirty-six patients with moderate-to-severe AD treated by dupilumab, and 9 of them treated for 2years. Changes in the severity scoring, pruritus numerical rating scale (NRS), patient-oriented eczema measure (POEM), serum levels of immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), eosinophils, and lactate dehydrogenase (LDH) at Week 0, 2, 4, 16, 48, 72, and 96 of those patients were investigated, and we studied features of the patients who had any adverse events (AEs). Results: Investigator's global assessment (IGA), eczema area and severity index (EAST), body surface area (BSA), NRS, POEM, and serum levels of LDH were significantly decreased from Week 4 onwards to Week 96 compared with baseline condition. Serum levels of TARC and LDH were significantly decreased from Week 4 onwards to Week 96. Regarding 9 patients who were treated with dupilumab for up to 2years, serum levels of TARC and eosinophils decreased without statistical significance. The serum levels of IgE significantly decreased at Week 72, 96 compared with the baseline. Regarding as AEs, ocular symptoms were the most frequently observed (15/36, 41.2%), and there were no cases of discontinuation due to AEs. Conclusions: Treatment with dupilumab was well tolerated and showed improvements in AD for at least 2 years.
引用
收藏
页码:88 / 93
页数:6
相关论文
共 50 条
  • [21] Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience
    Stingeni, L.
    Bianchi, L.
    Antonelli, E.
    Caroppo, E. S.
    Ferrucci, S. M.
    Ortoncelli, M.
    Fabbrocini, G.
    Nettis, E.
    Schena, D.
    Napolitano, M.
    Gola, M.
    Bonzano, L.
    Rossi, M.
    Fortina, A. Belloni
    Balato, A.
    Peris, K.
    Foti, C.
    Guarneri, F.
    Romanelli, M.
    Patruno, C.
    Savoia, P.
    Fargnoli, M. C.
    Russo, F.
    Errichetti, E.
    Bianchelli, T.
    Bianchi, L.
    Pellacani, G.
    Feliciani, C.
    Offidani, A.
    Corazza, M.
    Micali, G.
    Milanesi, N.
    Malara, G.
    Chiricozzi, A.
    Tramontana, M.
    Hansel, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) : 1292 - 1299
  • [22] A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis
    Napolitano, Maddalena
    Fabbrocini, Gabriella
    Potestio, Luca
    Fontanella, Giuseppina
    Picone, Vincenzo
    Bennardo, Luigi
    Scalvenzi, Massimiliano
    Patruno, Cataldo
    DERMATOLOGIC THERAPY, 2022, 35 (08)
  • [23] Real-world experience of dupilumab treatment for atopic dermatitis
    Martinez Mariscal, Jaime
    Cabana-Navia, Raquel
    Martinez-Fernandez, Alicia
    Martin-Fuentes, Adriana
    Checa-Recio, Ivan
    Gonzalez-Munoz, Patricia
    Sanchez-Herreros, Consuelo
    Vergara, Aranzazu
    Pastor-Nieto, Maria-Antonia
    Eusebio-Murillo, Esther
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB199 - AB199
  • [24] Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis
    Salman, Andac
    Sengun, Ozlem Apti
    Aktas, Meryem
    Taskapan, Oktay
    DERMATOLOGIC THERAPY, 2022, 35 (01)
  • [25] Real-world experience in the treatment of severe atopic dermatitis with dupilumab in Zurich, Switzerland
    Bersuch, Eugen
    Banziger, Kathrin
    Pacheco, Coronel Maria Veronica
    Galliker, Nadja
    Lars, French
    Schmid-Grendelmeier, Peter
    Glatz, Martin
    SWISS MEDICAL WEEKLY, 2018, 148 : 37S - 37S
  • [26] Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study
    Berna-Rico, Emilio
    Fiz-Benito, Esther
    Busto-Leis, Jose Manuel
    Servera-Negre, Guillermo
    de Lucas-Laguna, Raul
    Feito-Rodriguez, Marta
    DERMATOLOGY, 2024, 240 (02) : 337 - 342
  • [27] Dupilumab treatment in adult patients with moderate to severe atopic dermatitis: A real-world single-center experience from Turkey
    Salman, Andac
    Aktas, Meryem
    Ozkurkcu, Esra
    Sarac, Gonca
    Taskapan, Oktay
    Ergun, Tulin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB144 - AB144
  • [28] TREATGermany registry: "real-world effectiveness" of dupilumab in atopic dermatitis
    Weidinger, S.
    Stoelzl, D.
    Abraham, S.
    Haufe, E.
    Heratizadeh, A.
    Werfel, T.
    Schmitt, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : S236 - S236
  • [29] Real-world effectiveness of dupilumab for the treatment of atopic dermatitis in adult and pediatric patients
    Emmerich, Veronica K.
    Williams, Josiah
    Hrin, Matthew L.
    Newsom, Megan
    Feldman, Steven R.
    Strowd, Lindsay C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB199 - AB199
  • [30] Real-World Effectiveness and Safety of Baricitinib in Patients with Atopic Dermatitis
    Egídio Freitas
    Maria João Paiva Lopes
    Maria João Cruz
    Diogo Sousa
    Ana Clara Valente
    Bruno Duarte
    Laetitia Teixeira
    Gilberto Rosas
    Mónica Caetano
    Alberto Mota
    Paulo Filipe
    Tiago Torres
    Clinical Drug Investigation, 2024, 44 : 87 - 90